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Abstract 
Premature morbidity and mortality due to cardiovascular disease (CVD) disproportionately 
affects individuals with schizophrenia.  This research paper systematically reviews articles that 
examine the theories and causes of increased CVD risk in individuals with schizophrenia. The 
findings of the review indicate that there are biological, environmental and sociocultural 
components of the relationship between schizophrenia and cardiovascular disease.  Inflammation 
from the progression of chronic schizophrenia appears to play a part.  The side-effect profile of 
the medications used to treat schizophrenia cause CVD risk factors.  The secondary and tertiary 
symptoms of the disease process result in problems in motivation, cognitive function and self-
isolation, all which contribute to CVD risk.  Sociocultural factors such as increased poverty, 
homelessness and food insecurity are also higher in this population, which are associated with 
increased cardiovascular morbidity.  In conclusion, further research into contributing factors and 
funding for services is needed to better understand this issue and reduce the associated public 
health disparities. 
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Introduction 
Individuals with schizophrenia are dying earlier as compared to the general population1, 2. People 
with severe mental illness (including schizophrenia, major depression and bipolar disorder) are 
dying 10-25 years earlier and those with schizophrenia proper have a 2 to 2.5 times higher 
mortality rate.1 This profound discrepancy can be primarily attributed to cardiovascular disease1-4.  
Cardiovascular disease (CVD) is a broad term that encompasses many disease processes 
including but not limited to: coronary heart disease, atherosclerosis, hypertension, peripheral 
artery disease, cerebrovascular disease and stroke.  CVD has many risk factors and sequelae.  
The most pertinent risk factors in the schizophrenia population are diabetes mellitus (two to three 
times higher in individuals with schizophrenia1, 5), cigarette smoking, poor diet and physical 
inactivity.  Another important risk factor is metabolic syndrome, characterized by hypertension, 
hyperlipidemia, high blood glucose and centralized obesity5. 
Background on Schizophrenia and Cardiovascular Disease 
Schizophrenia is defined by the National Institute of Mental Health as a “chronic and severe 
mental disorder that affects how a person thinks, feels and behaves6.”  It is also characterized by 
a loss of touch with reality and a chronic disability in day-to-day functioning. In the DSM-V, the 
official diagnostic manual for mental health disorders7, schizophrenia is defined by the presence 
of both “positive” and “negative” symptoms.  Positive symptoms indicate the presence of 
symptoms that were not previously there, such as delusions, hallucinations or disorganized 
thoughts and behaviors.  Negative symptoms include flat affect, anhedonia (lack of pleasure in 
daily activities), amotivation and poverty of speech7.  Negative symptoms can present 
functionally as poor hygiene, lack of social skills and an inability to stay motivated or be a part 
of “normal” activities such as work, school or home life6. 
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 Cardiovascular disease (CVD) risk can be qualified through patient report.  This is via 
previously discussed risk factors such as cigarette smoking, metabolic syndrome and lack of 
physical activity.  One measure of quantifying cardiovascular risk is the ASCVD 10-year or 
lifetime risk scale adopted by the American Heart Association8.  This scale is widely accepted in 
the medical community as a way to quantify CVD risk, outcomes and choose appropriate 
treatment options.  The ASCVD looks at patient variables of lipid levels (LDL and HDL), 
cigarette smoking, age, blood pressure and gender to measure cardiovascular risk8.  There are 
alternative tools to use that take into account the patient’s ethnicity and racial background. 
Diabetes mellitus (DM2) is also well established as a CVD risk factor.  DM2 can be quantified in 
various ways, but in the literature most often the measurements used are HbA1C or C-peptide 
markers via serum laboratory draws5.   
Impact of Problem 
The evidence of premature mortality and significant morbidity from cardiovascular disease in 
people with schizophrenia is remarkable.  A large-scale meta-analysis completed in 2017 by 
Correll et. al2 found that 10% of individuals with severe mental illness have CVD by age 50.  By 
having a severe mental illness the lifetime risk of having CVD increases by 53% and there is an 
85% increased risk of CVD mortality.   
 There is an additional financial burden associated with the high incidence of 
cardiometabolic comorbidities in the schizophrenia population. This is attributed to increased 
inpatient hospital readmissions (within 30 days) and resulting increased monetary spending by 
taxpayers9.  All of this highlights the glaring public health disparity and crisis with which the 
medical community is currently faced.   
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 The increased incidence of morbidity and mortality from cardiovascular disease in 
individuals with schizophrenia is profound.  This is both a public health crisis and an economic 
problem and is a concern that the medical community needs to address.  There are initiatives and 
guidelines that are beginning to address these problems20, but the stigma and tertiary symptoms 
of schizophrenia are still barriers to prioritization of these issues within the medical community1.  
Continued research and education is key to ensure that this vulnerable population does not 
continue to slip through the cracks of our medical system. 
 
Literature Review 
The question is then raised—why do individuals with schizophrenia have a higher rate of 
cardiovascular disease (CVD) and premature mortality?  The answer is complex and dynamic, 
with many contributing factors.  The anti-psychotic medications used to treat schizophrenia play 
a significant part due to their side effects, which cause weight gain, metabolic symptoms and 
diabetes mellitus10.  The negative symptoms of schizophrenia itself can contribute as they affect 
a person’s motivation, cognition and functional ability to cook healthy meals and participate in 
regular physical activity1,24,25.  Severe mental illness is often linked to low socioeconomic status1, 
which is not often studied in terms of its impact on these individual’s cardiovascular health.  It is 
shown that low SES is linked to food deserts, poor diet and physical inactivity that cause an 
increased disparity in CVD risk factors1,24.  Individuals with low SES and schizophrenia both 
have a higher incidence of cigarette smoking6,24 compared to their more socioeconomically 
affluent counterparts, another risk factor for developing CVD6.  Lack of access to care and 
provider judgment can also play a part1, 11. Another developing theory for the significantly high 
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comorbidity is the inflammatory theory of schizophrenia, which postulates a possible biological 
or genetic link between the two disease processes12-14.  
Anti-Psychotic Medications and Cardiovascular Disease 
Anti-psychotic medications are first-line treatment for schizophrenia6. These include first-
generation medications such as Haldol, Thorazine and Clozapine, which are now generally 
reserved for refractory cases of schizophrenia due to possible irreversible neurological side 
effects.  The more commonly used medications are second-generation atypical antipsychotics 
(such as Depakote, Seroquel and Risperdal).  These atypical anti-psychotic medications, while 
much safer in terms of neurological side effects, can cause significant weight gain and obesity 
and have resulting diabetes mellitus and metabolic syndrome5, 6, 10, 15.  
 Studies are being done to try and extrapolate the incidence of metabolic syndrome (as a 
CVD risk factor) in patients with schizophrenia from anti-psychotic use.  Cordes et. al15 
completed a study comparing anti-psychotic naïve men and women with schizophrenia to 
healthy control participants.  They found increased incidence of metabolic syndrome 
(specifically increased blood pressure, waist circumference and blood glucose) in people with 
schizophrenia; although the findings were not significant enough to show that anti-psychotic 
naïve patients have an increased risk of developing metabolic syndrome.  The researchers did 
cite gaps in their data and that further research may show that anti-psychotic naïve patients do 
have an increased risk of developing metabolic syndrome independent of medication use. 
 In contrast, Catts and O’Toole16 decisively state that anti-psychotics do not significantly 
contribute to CVD morbidity and mortality in schizophrenic individuals. They report that instead 
long-term maintenance with anti-psychotic medications, particularly a bi-monthly injection 
medication such as Risperdal Consta, reduces symptoms and remissions and therefore manages 
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comorbidities.  The authors propose that CVD risk, morbidity and mortality are primarily 
associated with prolonged periods of psychosis without remission.  These prolonged periods of 
psychosis lead to both negative symptoms and a lack of insight and therefore poor preventative 
care and the associated symptoms of schizophrenia.  The caveat to this opposing point of view is 
that the authors of the article receive funding from Lilly, Janssen and other large pharmaceutical 
companies that produce atypical anti-psychotic medications. 
Inflammatory Theory of Schizophrenia 
The role of inflammation in disease processes and pathology has permeated recent medical 
research.  The effects of inflammatory processes are being investigated in relation to all systems 
of the body.  Research is now well established linking metabolic syndrome and cardiovascular 
disease to inflammatory processes.   There are various theories regarding the mechanisms of this 
process and it is being continuously refined and studied.  One theory poses that there is a link 
with adipocytokines from the gut and resulting inflammatory processes, and metabolic syndrome 
(and it’s sequelae of CVD)17. This specific theory highlights the complex interaction of 
hereditary, biological and environmental etiologies of metabolic syndrome and cardiovascular 
disease. 
 Research is now investigating schizophrenia as a function of inflammation and 
inflammatory processes12-14.  This theory revolutionized the study of the biological and 
physiological origins of severe mental illnesses, as previously the focus was on neurobiological 
and neurochemical processes.  The core of the research is looking at cytokines and various 
inflammatory markers (such as alpha-TNF) and their concentrations in people affected by severe 
mental illness (schizophrenia, in this case).  The prevailing premise is that the inflammatory 
processes that then happen in the brain could have neuropsychological sequelae.  Studies show 
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mixed findings as this research is new and still being understood.  This research again highlights 
the complex etiology and pathophysiology of schizophrenia and the contributions from both 
environment and genetics. 
 Balostev et. al14 used a case-control design to investigate the relationship between 
changes in specific inflammatory markers in individuals with schizophrenia with comorbidities 
of CVD and/or diabetes mellitus. Their findings were mixed, but increased pro-inflammatory 
markers, including cytokines and growth factors (IL-2 and ILF-y specifically), were present in 
individuals with chronic schizophrenia.  While the research showed that the progression of 
chronic schizophrenia was significantly linked to inflammation, the findings were vague when 
attempting to assign significance to a relationship with CVD presentations.  A key significant 
finding of the study was that individuals with schizophrenia who had CVD (as measured by a 
hyperlipidemia risk factor) showed signs of chronic pro/anti-inflammatory imbalance via their 
inflammatory disease-markers (cytokines and growth factors).  A point of note is that for some 
statistical analyses the researchers set their p-value to < 0.1 as opposed to the generally accepted 
p <0.05 as the lower value “failed to identify important variables for the final model.14” 
 These inflammatory processes could also have implications in the link between 
schizophrenia and metabolic syndromes.  Gut microbes and mircroflora and resulting 
inflammation and disease processes (such as celiac disease) is a well-studied process in the 
academia of gastrointestinal and dietary sciences.  Joseph et. al13 looked at inflammatory markers 
in the gut to discern if there were any significant changes in gut microbes and resulting immune 
dysfunction in people with schizophrenia.  Specifically they looked at short chain fatty acids, 
which are metabolites of dietary fiber by gut microbes.  Short chain fatty acids are metabolized 
by both immune and metabolic pathways, making them ideal for theoretical research comparing 
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neurobiological (schizophrenia) and metabolic disease processes. The findings were preliminary 
and there were no statistically significant causational findings noted.  The researchers did state 
that there was some evidence of increased gut inflammatory markers in people with 
schizophrenia, which would indicate a link to immune dysfunction and possible poor 
neuropsychological outcomes.   
Sociocultural Influence on CVD risk factors 
Socioeconomic (SES) and racial disparities affect outcomes in schizophrenia1,6,24.  Mangurian et 
al.18 found that diabetes mellitus was more prevalent in adults with severe mental illness than in 
the general population, a finding echoed by other studies2, 5.  Their data also indicated that non-
White adults with severe mental illness were at a two to three times increased risk of developing 
diabetes mellitus as compared to White adults.   
 Chronic schizophrenia is associated with poverty, unemployment, homelessness and 
social isolation1, 25, 27.  These states put individuals at risk for food insecurity and unhealthy diets, 
lack of health insurance, lack of access to healthcare and a general poor quality of life, all 
leading to an increased CVD risk1,24.  Individuals with chronic schizophrenia often end up 
unemployed25, and in the United States this would result in utilizing Social Security Income 
(income that is below the poverty limit) for financial support. Due to chronic disabling 
symptoms, they are also often estranged from family25 and many are living in homeless shelters 
or institutions.  All of these factors cause people with schizophrenia to rely on food stamps and 
food shelves for the context of their diet, often resulting in highly-processed, high-fat and 
carbohydrates and low in fresh fruits and vegetables28.  This also results in food insecurity, 
where individuals do not always have stable access to nutritious food. Additionally, there is a 
high incidence of homelessness within this population, which limits an ability to store food or 
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make healthy meals27.  Healthcare access is limited by insurance, transportation and ability to 
pay co-pays, which also has trickle-down effects on CVD health and risk factors. 
 Provider attitudes can be a barrier to quality care.  The World Health Care Organziation1 
indicates that one of the primary reasons for negative provider attitudes is due to stigma.  
General medical providers often have little understanding or knowledge about psychosis and 
schizophrenia.  This leads to misunderstanding, judgment and mistrust on both sides of the 
provider-patient relationship.  Schizophrenia is a disorder already defined by paranoia and 
altered thinking7, and this mistrust or misconstrued relationship can lead to a lack of engagement 
or a complete disengagement from medical care.  This is problematic as preventative care is key 
in both promoting a heart healthy lifestyle and screening and early treatment of cardiovascular 
risk factors.  
 The symptoms and progression of schizophrenia itself also play a part in increasing CVD 
risk factors1.  Negative symptoms of schizophrenia cause poor hygiene, social isolation and a 
lack of motivation6,7,28.  This can make it difficult for a person to exercise regularly, cook, 
prepare healthy meals and follow-up with medical care26,28 (often fraught with complex labs, 
appointments and instructions)19. Additionally social isolation is independently associated with 
increased symptoms of inflammation, food insecurity and poor nutrition—all linked to CVD risk 
factors28. Schizophrenia is also associated with increased substance abuse, including cigarette 
smoking2.  Cigarette smoking is considered a CVD risk factor per the ASCVD 10 year risk 
guidelines8. 
Interventions for reducing cardiovascular risk factors 
The chronic and pervasive nature of cardiovascular morbidity and mortality in individuals with 
schizophrenia is clear.  So what can we, as a medical community, do to address this issue?  
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Public health awareness around this topic is increasing. Healthy People 2020 initiatives through 
the Office of Disease Prevention and Health Promotion20 are specifically indicating a need for 
primary care clinics to integrate mental health services on site.  These public health initiatives 
will ideally be implemented across the nation by the year 2020 and their focus on integration of 
services emphasizes increased awareness. 
Exercise-specific Interventions 
Increased physical activity is a healthy lifestyle factor that can reduce cardiovascular risk8.  
Naslund et. al21 studied increased physical activity in people with severe mental illness as a 
function of utilizing “wearable devices” (such as a Fit Bit).  The study participants wore the 
devices daily, were given recommendations to complete 150 minutes of moderate exercise per 
week, intake a healthy diet and received personal support services through the study.  The 
findings were mixed on whether or not the “wearable devices” themselves increased fitness 
(although the participants did lose weight during the study).  The researchers indicated that 
adherence, health literacy and cost were all barriers in generalizing use of the devices outside of 
their study parameters.  
 Other research indicates that in people with schizophrenia the most influential factor in 
increasing physical activity is with a health professional’s specific encourgament19.  The research 
by Twyford and Lushford19 indicated that any encouragement or mention regarding physical 
activity by a health professional, no matter the context, was at least mildly effective.  This is a 
key point for primary care and medical providers as it is an easy intervention to implement at any 
preventative appointment.  
Diet-specific interventions 
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Regular consumption of a heart-healthy diet will reduce cardiovascular risk8.  The Mediterranean 
Diet could have an increased potential to reduce CVD risk in people with schizophrenia as it may 
target specific gut metabolites and inflammatory processes13.  These findings were statistically 
insignificant however, and the researchers cautioned that further research needed to be done 
before definitively saying that the Mediterranean Diet is the best diet for reducing CVD risk in 
schizophrenia. Evidence still exists that it is an effective heart-healthy diet, although one of many 
options (such as the DASH diet, or general reduction of dietary saturated fat)23. 
Provider-specific Interventions 
Healthcare providers are often unfamiliar or uncomfortable with schizophrenia and healthcare 
clinics do not have mental healthcare integrated on site1, 20. Researchers polled primary care 
providers on whose role it was to follow up on metabolic monitoring of individuals taking anti-
psychotic medications: the patient’s primary care provider or their psychiatrist 11.  The 
researchers received three different responses from the providers: 1) primary care provider’s role 
to prescribe the medications and monitor 2) psychiatrist’s role to do both 3) psychiatrist should 
prescribe and the primary care should do the metabolic monitoring.  In this case, it is likely that 
some patients psychiatric and/or CVD care was falling through the cracks, which could easily 
contribute to increased morbidity and mortality. These findings indicate that coordination of care 
between medical and mental health providers is crucial.   
 A Cochrane Review22 analyzed the effectiveness of offering general physical advice to 
people with severe mental illness.  They found that offering only general advice as a medical 
provider was a statistically ineffective intervention at improving patient outcomes and quality of 
life.  This shows the need for focused, specific interventions when it comes to reducing CVD risk 
in individuals with schizophrenia.!
!
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Methods 
Pub Med database through the Augsburg Lindell Library was searched for any articles 
containing the keywords “schizophrenia,” “serious mental illness,” “cardiovascular disease,” and 
“metabolic syndrome”. The researcher initially reviewed 47 articles, which needed to include 
information on both schizophrenia and cardiovascular disease.  Thirty-five of those articles were 
moved into RefWorks database for further review. The articles were then narrowed down via 
abstract and availability (two articles were not available via inter-library loan) as they pertained 
to the research question.  Articles that looked only at non-CVD risk factors (such as fatty liver or 
diabetes mellitus), genetic markers or specific populations (such as the elderly, racial groups or 
long-term inpatient patients) were discarded.  Initially sixteen peer-reviewed articles were 
included in the review.  As the researcher reviewed the articles and supplemental information 
was needed six articles were added. Twenty-two peer-reviewed articles, one response to a peer-




The literature demonstrates that there is undeniably a relationship between cardiovascular 
disease, schizophrenia and premature morbidity and mortality1-5.  Individuals with schizophrenia 
are losing 10-25 years of their life compared to the general population, most commonly due to 
CVD complications1-3.  
 This relationship is a complex one, and there is no obvious cause and effect for the 
increased incidence of CVD morbidity and mortality in the schizophrenia population.  The 
literature clearly indicates that the medications we prescribe to treat schizophrenia are a 
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contributing factor.  These anti-psychotic medications have side-effect profiles that directly 
cause dyslipidemia, metabolic syndrome and obesity5, 6, 10, 15.  In this sense, a direct line can be 
drawn between anti-psychotic medications and cardiometabolic risk factors.  There are some 
researchers that disagree with this line of thought16, but the majority of the available research 
overwhelmingly agrees that the increase in CVD risk factors associated with the medications is 
related to the increased CVD morbidity in this population.  
 Social factors of schizophrenia are also linked to an increase in cardiovascular risk 
factors. Tertiary symptoms of schizophrenia expressed as a disability in daily function are 
associated in the literature to cardiovascular risk factors.  Low socioeconomic status and chronic 
schizophrenia are closely tied1,27, and less affluent individuals are more likely to be physically 
inactive, have poor diets, eat less fruits and vegetables and have less access to healthy foods24,28.  
Symptoms of schizophrenia also are stigmatized1, within both the general population and 
medical community.  This can affect access to healthcare and treatment, both which can 
influence cardiovascular outcomes22.  The natural progression of schizophrenia itself can present 
as symptoms of poor hygiene and self-care as well as a lack of motivation6,7,28, all of which can 
contribute to an overall poor quality of health. 
 A new and exciting area of research associated with the progression of schizophrenia is 
inflammation.  While there is much evidence within the literature that there are increased 
inflammatory markers (biological markers that get released when inflammation is present in the 
body) associated with schizophrenia12-14, there currently is no clear tie to cardiovascular disease.  
Researchers are postulating that there is a link between the inflammatory theory of gut microbes 
(associated with metabolic syndrome, a CVD risk factor) and schizophrenia but no significant 
statistical evidence has been found to support this theory13.  The continued theme throughout the 
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literature is that more studies need to be done, as there will be significant findings once the 
research techniques are honed further12-14.  If this is true, there will be profound implications for 
our abstract understanding of both the hereditary and genetic causes of schizophrenia and it’s 
connections to CVD.  
Conclusions 
Premature mortality and morbidity due to cardiovascular disease in schizophrenia is a public 
health issue that demands further research and resource allocation.  Individuals with 
schizophrenia are often overlooked and fall through the cracks of our medical system due to lack 
of understanding and stigma1.  This has caused profound disparities resulting in a mortality gap 
that needs to be addressed as it will continue to widen for the schizophrenia population. 
 Funding for new research is currently being focused on biological and hereditary causes 
of schizophrenia and it’s association with CVD, specifically inflammatory causes12-14.  
Statistically significant results from this research would be invaluable, allowing us to specifically 
target medications and interventions to reduce inflammation and therefore reduce both mental 
health symptoms and CVD risk factors. 
 Resource allocation into programs implementing services and interventions for 
individuals with schizophrenia to reduce CVD risk factors (such as metabolic syndrome, 
physical inactivity, cigarette smoking) is essential.  These services and interventions need to be 
implemented in an evidence-based, systematic approach to be of value, as the research shows 
mixed results of interventions13,19,21,22.  Careful monitoring and continued public health oversight 
into this issue will allow for a systematic approach to intervention that will ideally begin to 
reduce the mortality and morbidity disparity for individuals with schizophrenia. 
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 There also would be value in programs or seminars offered to the medical community 
addressing stigma and misconceptions around schizophrenia.  This intervention could improve 
provider’s attitudes towards patients with schizophrenia and catalyze change in engagement and 
access to healthcare visits for this population.  Conversely, seminars or trainings could also be 
offered within the mental health community on how to integrate physical health interventions 
into their practice.  Continued advocacy by public health organizations like Healthy People 
202020 to integrate physical and mental health services and encourage active communication 
between the two communities is also key to ensure that both CVD and schizophrenia are being 
addressed concurrently. 
 Premature cardiovascular morbidity and mortality is affecting individuals with 
schizophrenia. This is a public health issue that concerns the medical community.  We have the 
tools and resources to address and begin to resolve the contributing disparities. With a continued, 
collaborative effort as medical providers we can close the mortality gap and ensure a healthier 
and happier quality of life for all of the people that we serve.  
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